Several of the world’s most important tuberculosis clinical trials of the last two decades were done in part or entirely in South Africa. Tiyese Jeranji chatted to some leading researchers about where the country’s clinical trial capacity comes from and what is needed to maintain and improve it.
During South Africa’s COVID-19 hard lockdown, rising star scientist Dr Sandile Cele spent his Christmas holidays in a laboratory. Soon the 35-year-old became the first to successfully grow the beta variant of SARS-CoV-2 in the lab. Biénne Huisman spoke to Cele about how he did this, the string of accolades he received since, and his leap from a modest upbringing to the global scientific stage.
South Africa’s National Strategic Plan for HIV, TB and STIs (2023 – 2028) was launched on Friday at Tlhabane Stadium in Rustenburg, North West as the world commemorated World TB Day. Nthusang Lefafa attended the event and spoke to experts and activists about the state of TB and HIV and the work that lies ahead with the new NSP.
According to the World Health Organization, of the roughly 10 million people who fall ill with TB annually, over 80% survive, in most cases due to a six-month treatment course. Unfortunately, as with long COVID, being cured is not always the last hurdle and many people go on to struggle with post-TB lung disease. Tiyese Jeranji asked local experts about this sometimes-neglected area of TB care.
COVID-19 has pushed back our progress on tuberculosis, but we can claw back our gains when we work collaboratively and efficiently, writes Kelvin Vollenhoven and Neetha Morar.
Local researchers have welcomed impressive phase III findings for the Russian-made Sputnik V vaccine published this week in the Lancet medical journal. It is the sixth COVID-19 vaccine found to be effective in preliminary data from a phase III randomised controlled trial and the fourth to have phase III findings published in a leading medical journal.
